Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | FABP6 | P51161 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033057 | 0.89 | GAA (0.59) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL2463599 | 0.87 | KDM4E (0.57) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL11316074 | 0.87 | BRD4 (0.70) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL7233513 | 0.85 | BRD4 (0.60) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL16487173 | 0.85 | GAA (0.58) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL16891491 | 0.84 | GAA (0.54) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL28887010 | 0.80 | GAA (0.53) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL15033026 | 0.80 | KDM4E (0.54) | GAAKDM4ELMNABRD4BRD2 | |
| SCHEMBL200 | 0.79 | LOXL2 (0.66) | GAAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5443026 | 0.79 | LMNA (0.60) | GAAKDM4ELMNAMAPK10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-05-23 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| EP-3033336-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-30 | — | — | EP | disclosed |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | GAA 722/4885KDM4E 1741/4885LMNA 110/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | GAA 722/4885KDM4E 1741/4885LMNA 110/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | GAA 722/4885KDM4E 1741/4885LMNA 110/4885 |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | GAA 722/4885KDM4E 1741/4885LMNA 110/4885 |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, SERPINB1, KLK5 | GAA 722/4885KDM4E 1741/4885LMNA 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.